Artia Global Partners LP Invests $4.93 Million in Sionna Therapeutics, Inc. $SION

Artia Global Partners LP acquired a new position in Sionna Therapeutics, Inc. (NASDAQ:SION) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 119,741 shares of the company’s stock, valued at approximately $4,926,000. Sionna Therapeutics makes up 0.7% of Artia Global Partners LP’s holdings, making the stock its 22nd largest holding. Artia Global Partners LP owned approximately 0.27% of Sionna Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SION. Goldman Sachs Group Inc. bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth $667,000. Woodline Partners LP acquired a new stake in shares of Sionna Therapeutics during the first quarter worth $837,000. Geode Capital Management LLC raised its position in shares of Sionna Therapeutics by 113.4% during the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares during the period. Rhumbline Advisers acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $307,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $118,000.

Sionna Therapeutics Trading Up 5.7%

Shares of NASDAQ SION opened at $36.73 on Thursday. Sionna Therapeutics, Inc. has a one year low of $13.81 and a one year high of $48.44. The firm has a market capitalization of $1.66 billion, a PE ratio of -19.03 and a beta of 1.30. The business has a 50-day moving average price of $39.87 and a two-hundred day moving average price of $39.50.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Research analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 184,639 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the transaction, the director owned 2,671,822 shares in the company, valued at $123,491,612.84. This trade represents a 6.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,717,962 shares of company stock valued at $77,571,889 over the last 90 days. Corporate insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SION shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. JonesTrading boosted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Wall Street Zen lowered Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Guggenheim boosted their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Freedom Capital lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.22.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.